These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The treatment of carcinoma in situ of the breast].
    Author: Raudrant D, Golfier F, Unger P.
    Journal: Rev Fr Gynecol Obstet; 1990 Feb; 85(2):91-6. PubMed ID: 2157271.
    Abstract:
    In reference to a series of 36 in situ breast carcinomas, the current therapeutic possibilities are considered: 8 lobular carcinomas in situ (LCIS) and 28 ductal carcinomas in situ (DCIS) were diagnosed between January 1985 and July 1988. These are infraclinical forms in 80% of the cases, representing 20% of the breast carcinomas treated during the same period of time. The natural history of carcinomas in situ is presented; LCIS rarely evolve toward an invasive carcinoma and they should not be considered as risk factors. DCIS evolve, after biopsy, toward an infiltrating ductal carcinoma in 26 to 28% of the cases. Axillary node invasion is present in 3% of the cases. After diagnostic biopsy of a LCIS, a subcutaneous mastectomy with prosthetic reconstruction will be offered only if there are bilateral foci or diffuse microcalcifications. Supervision will be recommended in all other cases. The results of the mastectomy-node excision procedure are well known for the LCIS: less than 5% recurrence and a mortality under 1.5%. The current tendency goes toward a limited surgical act: axillary dissection is discussed for small LCIS; lumpectomy is more and more advocated with long-term results still not well known; in case of lumpectomy, two prospective trials are currently in progress in the world, in order to assess the efficacy of radiotherapy.
    [Abstract] [Full Text] [Related] [New Search]